Patent Yard Sign in
Expired Canadian patentCanada

Imidazo 1,2-a imidazoles, their acid addition salts, pharmaceuticals comprising same and processes for their production thereof

CA 1115280 A · Owner: Boehringer Ingelheim G.M.B.H. · Inventors: Kummer, Werner; Koppe, Herbert; Stahle, Helmut

CIPO record

Overview

Drawings and full text

Its claims, description and drawings are in the Canadian Patents Database.

Open the CIPO record

Abstract From the Canadian patent

Imidazo1,2-aimidazoles of general formula I, (wherein R1, R2 and R3 independently represent hydrogen fluorine, chlorine, bromine, methyl, methoxy or trifluoromethyl but at least one of R1, R2 and, R3 is other than hydrogen; R4 and R5 independently represent hydrogen or methyl) and pharmaceutically acceptable acid addition salts thereof. The compounds have been found to decrease heart beat frequency and may therefore be useful in the treatment of coronary diseases. Processes for the preparation of the compounds, and pharmaceutical compositions containing them are, described and exemplified.

Read the whole patent

Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.

Why it's free to use

  • Granted December 29, 1981. A Canadian patent filed before October 1, 1989 lasted 17 years from grant, so its term ended December 29, 1998.
  • We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledJune 22, 1979
GrantedDecember 29, 1981
Term endedDecember 29, 1998
Patent numberCA 1115280 A
Classification (IPC)C07D487/04

Timeline

Timeline From CIPO dates

1980198219841986198819901992199419961998Application filedJune 22, 1979Patent grantedDec 29, 1981Term endedDec 29, 1998

Sources & verification

Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.